Runnebaum, Ingo B.
Reichert, Dietmar
Ringsdorf, Uta
Kuther, Markus
Hesse, Tobias
Sehouli, Jalid
Wimberger, Pauline
Funding for this research was provided by:
PharmaMar (ET-D-022-11)
Article History
Received: 21 March 2018
Accepted: 28 March 2018
First Online: 6 April 2018
Compliance with ethical standards
:
: Ingo Runnebaum has received funding for this study and a speaker honorarium from PharmaMar and was a member of advisory board of PharmaMar. Jalid Sehouli is a member of advisory board of Roche, Clovis, Tesaro and Astra Zeneca, and has received founding from PharmaMar and Medac. Pauline Wimberger has received a speaker honorarium from PharmaMar for scientific talks. All other authors declare they have no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards, guidelines for Good Pharmacoepidemiology Practice and the German Drug Law (AMG, ยงย 67[6]), and were approved by the institutional review boards of each participating center.
: Informed consent was obtained from all individual participants included in the study.